NCT07381413 Eye Tracking Study on Eye Movement Function and Visual Attention Patterns in Patients With Thyroid-Associated Ophthalmopathy
| NCT ID | NCT07381413 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Changzheng Hospital |
| Condition | Thyroid Associated Ophthalmopathies |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-01-31 |
| Primary Completion | 2029-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2026-01-31 with a primary completion date of 2029-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study focuses on eye health and visual function in patients with Thyroid-Associated Ophthalmopathy (TAO), a condition that often causes bulging eyes and restricted eye movement. The purpose of this study is to use non-invasive eye-tracking technology to evaluate how the disease affects eye movement function. The investigators hypothesize that compared to healthy individuals, patients with TAO will show measurable differences in eye stability and the ability to track moving objects. Additionally, the investigators believe the disease may alter how patients visually scan faces (e.g., avoiding eye contact). The study will enroll 100 participants, including both patients and healthy volunteers. By recording gaze patterns while participants look at a screen, the investigators aim to objectively quantify the physical and social impact of the disease, providing better data for future treatment plans.
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 70 years, inclusive. * Willing and able to provide written informed consent. * Best-corrected visual acuity (BCVA) ≥ 1.0 in both eyes, with no history of ocular diseases or thyroid disorders. Exclusion Criteria: * Non-TAO Ocular Motility Disorders: History of conditions like myasthenia gravis, cranial nerve palsy, or congenital strabismus. * Neurological Diseases: Disorders affecting oculomotor control (e.g., Parkinson's, MS, stroke, or brain tumors). * Significant Visual Impairment: BCVA \< 0.5 due to media opacities or retinopathy, preventing clear visualization of stimuli. * Prior Ocular Surgery: History of surgeries affecting extraocular muscle mechanics (e.g., strabismus surgery, scleral buckling). * Psychiatric or Cognitive Disorders: Inability to follow instructions or conditions affecting eye movements (e.g., schizophrenia). * Medication Interference: Use of drugs affecting reaction time (e.g., sedatives) within 48 hours of testing.
Frequently Asked Questions
Who can join the NCT07381413 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Thyroid Associated Ophthalmopathies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07381413 currently recruiting?
Yes, NCT07381413 is actively recruiting participants. Visit ClinicalTrials.gov or contact Shanghai Changzheng Hospital to inquire about joining.
Where is the NCT07381413 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07381413 clinical trial?
NCT07381413 is sponsored by Shanghai Changzheng Hospital. The trial plans to enroll 100 participants.